TG Therapeutics Revenue vs. Return On Equity
| TGTX Stock | USD 34.61 0.46 1.31% |
Total Revenue | First Reported 1996-03-31 | Previous Quarter 73.5 M | Current Value 83.9 M | Quarterly Volatility 20 M |
For TG Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of TG Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well TG Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between TG Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of TG Therapeutics over time as well as its relative position and ranking within its peers.
TGTX |
TG Therapeutics' Revenue Breakdown by Earning Segment
Check out World Market Map.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of TG Therapeutics. If investors know TGTX will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about TG Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.97) | Earnings Share (0.10) | Revenue Per Share 1.829 | Quarterly Revenue Growth (0.49) | Return On Assets (0.0007) |
The market value of TG Therapeutics is measured differently than its book value, which is the value of TGTX that is recorded on the company's balance sheet. Investors also form their own opinion of TG Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is TG Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because TG Therapeutics' market value can be influenced by many factors that don't directly affect TG Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between TG Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if TG Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, TG Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
TG Therapeutics Return On Equity vs. Revenue Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining TG Therapeutics's current stock value. Our valuation model uses many indicators to compare TG Therapeutics value to that of its competitors to determine the firm's financial worth. TG Therapeutics is currently regarded number one company in revenue category among its peers. It also is currently regarded as top stock in return on equity category among its peers . At this time, TG Therapeutics' Total Revenue is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the TG Therapeutics' earnings, one of the primary drivers of an investment's value.TGTX Revenue vs. Competition
TG Therapeutics is currently regarded number one company in revenue category among its peers. Market size based on revenue of Health Care industry is at this time estimated at about 379.47 Million. TG Therapeutics totals roughly 233.66 Million in revenue claiming about 62% of equities under Health Care industry.
TGTX Return On Equity vs. Revenue
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
TG Therapeutics |
| = | 233.66 M |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
TG Therapeutics |
| = | -0.0805 |
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
TGTX Return On Equity Comparison
TG Therapeutics is currently under evaluation in return on equity category among its peers.
TG Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in TG Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, TG Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of TG Therapeutics' change in net profit over the period of time. It can combine multiple indicators of TG Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Operating Income | 20.6 M | 21.7 M | |
| Income Before Tax | 13.1 M | 13.7 M | |
| Total Other Income Expense Net | -7.6 M | -7.2 M | |
| Net Income | 12.7 M | 13.3 M | |
| Income Tax Expense | 390 K | 370.5 K | |
| Net Loss | -164.4 M | -172.6 M | |
| Net Income From Continuing Ops | 12.7 M | 13.3 M | |
| Non Operating Income Net Other | 2.1 M | 1.1 M | |
| Interest Income | 6.1 M | 6.4 M | |
| Net Interest Income | -12.6 M | -12 M | |
| Change To Netincome | 21.9 M | 23 M | |
| Net Income Per Share | 0.09 | 0.09 | |
| Income Quality | (2.48) | (2.35) | |
| Net Income Per E B T | 0.97 | 1.03 |
TGTX Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on TG Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of TG Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the TG Therapeutics' important profitability drivers and their relationship over time.
Use TG Therapeutics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if TG Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in TG Therapeutics will appreciate offsetting losses from the drop in the long position's value.TG Therapeutics Pair Trading
TG Therapeutics Pair Trading Analysis
The ability to find closely correlated positions to TG Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace TG Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back TG Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling TG Therapeutics to buy it.
The correlation of TG Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as TG Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if TG Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for TG Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your TG Therapeutics position
In addition to having TG Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Momentum Thematic Idea Now
Momentum
Large corporations operating in software, education, financial and car manufacturing industries. The Momentum theme has 40 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Momentum Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for TGTX Stock Analysis
When running TG Therapeutics' price analysis, check to measure TG Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TG Therapeutics is operating at the current time. Most of TG Therapeutics' value examination focuses on studying past and present price action to predict the probability of TG Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TG Therapeutics' price. Additionally, you may evaluate how the addition of TG Therapeutics to your portfolios can decrease your overall portfolio volatility.